Patients with relapsed or refractory multiple myeloma who are treated with new therapy combinations remain on their treatments far shorter than those participating in clinical…
News
Newly diagnosed multiple myeloma patients respond better to treatment when Empliciti (elotuzumab) is added to a combination of Revlimid (lenalidomide) and dexamethasone,…
The U.S. Food and Drug Administration (FDA) has agreed to extend Xgeva‘s (denosumab) approval to include patients with multiple myeloma who have bone lesions. The…
A preclinical study has shown that a new dual-targeting APRIL CAR T-cell therapy appears to be better at eliminating multiple myeloma cells than conventional CAR T-cell…
Janssen Biotech and China’s Legend Biotech are teaming up to continue developing and to market Legend’s CAR T-cell therapy for multiple myeloma. A hot…
BioLineRx has launched a Phase 3 trial to assess if adding BL-8040 to standard treatment will improve the outflux of blood stem cells from…
A collaboration between GNS Healthcare and the Multiple Myeloma Research Foundation (MMRF) resulted in the discovery of a biomarker called CHEK1 that detects which…
The European Commission has granted orphan drug status to CellProtect as a treatment for multiple myeloma, according to the investigational therapy’s developer, CellProtect…
An Adaptimmune therapy that strengthens immune T-cells’ response to cancer has helped patients with advanced myeloma live as long as five years without their disease progressing,…
Weighing individual cancer cells could help doctors predict how multiple myeloma patients will respond to treatments, a Massachusetts Institute of Technology study reports. The findings could…
